Earnings Alerts on Alibaba, JD, and Tencent
After a strong return in Chinese technology stocks in the last year, their earnings reports offered a mixed message.E-Commerce leader Alibaba (BABA) pulled back on May 15, 2025, after posting quarterly results. In the fiscal fourth quarter, revenue grew by 7% Y/Y to $32.58 billion. Results are positive overall. Despite the weak economic backdrop, net income grew by 1,203%. Alibaba benefited from strong demand in its AI, Cloud Intelligence, and AI-related products.Alibaba’s e-commerce platforms also performed well. Taobao and Tmall group reported a 12% increase in revenue.JD.com (JD) reported a 16% Y/Y increase in total revenue. The company enjoyed strong Online retail sales and total retail sales. The company is anticipating strong operational tailwinds throughout 2025. At the current 618 sales event, expect cheap product goods to drive sales and net margins.In the gaming segment, Tencent (TCEHY) posted strong results. Revenue of RMB180B is up 12.9% Y/Y. Revenue from online advertising, fintech, and business services helped lift Tencent’s results.The AI sector is another growth opportunity for Tencent. For example, Agentic AI is a concept that will help Tencent get questions answered quickly. It may also complete complex tasks. Watch out for Tencent reporting higher efficiencies as it implements this type of AI.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


